Page 1

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. © 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. Investor Day October 21, 2026 | New Y ork City

Page 2

© 2026 4D Molecular Therapeutics. All Rights Reserved. 2 Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, otherthan statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, regulatory interactions, timing, strategy, future operations, future financial position, prospects, plans, objectives of management, and implied and express statements regarding the therapeutic potential, treatment burden reduction,durability and clinical benefits of and market potential of our product candidates are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,”“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward looking statements, althoughnot all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation. This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied. This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

Page 3

Page 4

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 44 Key Takeaways For T oday Backbone therapy with the potential for lifelong, continuous disease control from a single dose1 Clinical trial data, Phase 3 design and strong execution positions us for success3 Target product profile that addresses the key unmet needs of patients : preserving vision while reducing treatment burden , with an opportunity for injection - freedom 2 Patients, physicians and payers together are expected to drive robust and broad commercial adoption 4 4D-150 Has the Potential to Establish A NEW TREATMENT PARADIGM IN WET AMD

Page 5

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 55 T oday's Speakers 4D MOLECULAR THERAPEUTICS David Kirn, MD Co-Founder, President & CEO Dhaval Desai, PharmD Chief Development Officer Chris Simms Chief Commercial & Business Officer Catherine Pajak Vice President, Commercial RETINA SPECIALISTS Sara Haug MD, PhD Southwest Retina Consultants Carl Awh MD, FASRS Tennessee Retina Arshad Khanani MD, MA, FASRS Sierra Eye Associates David Eichenbaum MD, FASRS Retina Vitreous Associates of Florida

Page 6

© 2026 4D Molecular Therapeutics. All Rights Reserved. 6 Agenda TOPIC SPEAKER Introduction David Kirn, MD Wet AMD Treatment Paradigm, Unmet Needs Arshad Khanani, MD, MA, FASRS 4D-150 PRISM Phase 1/2 Data & 4FRONT Phase 3 Program Carl Awh, MD, FASRS, Dhaval Desai, PharmD KOL Conversation (Moderated by Dhaval Desai): Promise of 4D-150 in Wet AMD Arshad Khanani, MD, MA, FASRS, Carl Awh, MD, FASRS Commercial Opportunity for 4D-150 Chris Simms, Catherine Pajak KOL Conversation (Moderated by Catherine Pajak): Patient Perspectives Sara Haug, MD, PhD KOL Conversation (Moderated by Chris Simms): Real World Adoption David Eichenbaum, MD, FASRS Go Forward & Q&A David Kirn, MD, All

Page 7

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 77 EPISODIC ADMINISTRATION Current Anti-VEGF Therapy Cannot Continuously Control Wet AMD HIGH BURDEN VISION IS LOST

Page 8

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 8 4D-150 Has The Potential T o Set a New Backbone Therapy Paradigm For Wet AMD ONE -TIME TREATMENT Backbone therapy with the potential for continuous, lifelong disease control LOWER BURDEN Minimal ongoing supplemental injections with an opportunity for injection-freedom VISION PRESERVED Initial vision gains are preserved 1X

Page 9

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 9 4D-150 is Designed for Low Dose, Targeted Delivery of Robust Aflibercept- Producing Transgenes to the Retina with a Single Intravitreal Injection *Regeneron data on file. 1. Calton et al. Invest Ophthalmol Vis Sci 2024;65:1. 2. Russell SR. Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years. Presented at: American Society of Retina Specialists Annual Meeting; 2024; Stockholm, Sweden. Kiss S, Gambuzza L. ASRS 2026: Ixo-vec gene therapy sustains reduced anti-VEGF burden at 5 years in wet AMD. Modern Retina/Ophthalmology Times. July 21, 2026. R100 Capsid Capsid base Peptide insertions Anti-VEGF Transgenes  Robust delivery to multiple retinal layers  Low doses and minimal inflammation potential  Primate-evolved  >64 million doses administered WW since launch* Aflibercept (VEGF Trap) VEGF-C RNAi  Enhanced aflibercept expression in preclinical studies1 In-office delivery with a favorable, predictable safety profile for potentially lifelong anti-VEGF expression2

Page 10

Page 11

© 2026 4D Molecular Therapeutics. All Rights Reserved. 11 Mismatch of Wet AMD Biology vs. Bolus Anti-VEGF Treatment Paradigm: Continuous Disease Control Not Achieved VEGF, vascular endothelial growth factor; IVT, intravitreal. 1. EYLEA® (aflibercept) U.S. Prescribing Information, §2.5; Venkatesh R, et al. Indian J Ophthalmol. 2026;74(5):748–759. doi:10.4103/IJO.IJO_3284_25. Annual injection frequency calculated from every-8-week maintenance dosing; excludes loading doses. BIOLOGY -TO-TREATMENT MISMATCHDisease Biology  Chronic, vision-threatening  Heterogeneous, variable disease activity (fluid accumulation, swelling and bleeding) CONTINUOUS DISEASE ACTIVITY Variable & Persistent Recurring injections and office visits EPISODIC TREATMENTAnti-VEGF Conc. ~6 injections/year 1 Bolus Anti- VEGF Therapy Paradigm  3 loading doses  T reat & extend  High treatment burden

Page 12

© 2026 4D Molecular Therapeutics. All Rights Reserved. 12 In the Real World, Vision is Not Maintained Long-term and is Associated with Fewer Bolus Anti-VEGF Injections VA, visual acuity; ETDRS, early treatment diabetic retinopathy study. 1. Wykoff et al.: Ophthalmol Sci. 2023 Oct 31;4(2):100421.; n=135,384 at Yr 1; 6,878 at Yr 6. 2. Singer MA, et al. Ophthalmology. 2012;119(6):1175–83. 3. Silva R, et al. Ophthalmology. 2012;120:130–39. 4. Maguire MG, et al. Ophthalmology. 2016;123:1751–61. 5. Khanani A, et al. Ophthalmology. 2019;4(2):122–33. 6. Ciulla T, et al. Ophthalmology. 2019;4(1):19–30. 7. Arpa C, et al. Br J Ophthalmol. 2021;105(12):1688–95. 3 1.2 -0.4 -1.8 -3.1 -4.6 Change in VA, ETDRS Letters Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6Yr 0 REAL WORLD VISUAL ACUITY ON ANTI -VEGF 1 Early gains are not sustained over time ANTI -VEGF INJECTION FREQUENCY DECLINES 1 Avg. # of injections  T otal injections ~31  7.2 5.6 4.6 4.5 4.6 4.2 Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6Yr 0 REAL -WORLD STUDIES HORIZON2 SECURE3 CATT4 SIERRA-AMD5 Ciulla et al.6 Arpa et al.7 The real world challenge is not the initial response, it is maintaining the response long-term

Page 13

© 2026 4D Molecular Therapeutics. All Rights Reserved. 13 High Attrition in the Real World Further Highlights the Limitations of the Bolus Anti-VEGF Paradigm 1. Moshfeghi DM, et al. Invest Ophthalmol Vis Sci. 2026;67:5268. ARVO 2026. 2. Vakharia PS, et al. Invest Ophthalmol Vis Sci. 2026;67:5267. ARVO 2026. 3. MacCumber MW, et al. Can J Ophthalmol. 2023;58:252–261. 100% ~60% ~50% <40% At Tx start After 12 months After 3 years After 5 years PATIENTS FALL OFF THERAPY OVER TIME 1 - 3

Page 14

© 2026 4D Molecular Therapeutics. All Rights Reserved. 14 ASRS PAT1 Survey Shows Need for Longer-Lasting Therapies and Identifies Gene Therapy as the Most Exciting Pipeline Treatment 1. Hahn P, ed. ASRS 2025 Preferences and Trends Membership Survey. Chicago, IL. American Society of Retina Specialists; 2025. WHAT DO YOU THINK IS THE BIGGEST UNMET NEED IN WET -AMD THERAPEUTICS? 65.0% 62.1% 64.0% 42.1% 34.5% 17.1% 72.0% 64.4% 55.6% 44.0% 43.2% 22.4% Therapies for Concurrent dry AMD/Atrophy Therapies to Restore Vision Lost from Fibrosis Therapies Beyond VEGF Inhibition Non-Injectable Therapies Better Drying Agents Longer-Lasting Therapies 18.3% 12.6% 2.6% 4.2% 12.2% 0.4% 44.0% 9.2% 20.4% 4.8% 8.4% 13.2% 0.0% Gene Therapy Tyrosine Kinase Inhibitors VEGF-C/VEGF-D Inhibitors Novel Mechanism Agents None of the Above I Do Not Know Other WHICH PIPELINE TREATMENT FOR WET AMD EXCITES YOU MOST? 49.7% ~65% ~50% U.S. International

Page 15

© 2026 4D Molecular Therapeutics. All Rights Reserved. 15 Continuous Anti-VEGF Delivery (SUSVIMO®) Achieves Long-term Vision Preservation Through 7 Years1 BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; nAMD, neovascular age-related macular degeneration; PDS, port delivery system; VEGF, vascular endothelial growth factor. 1. Khanani AM, Oral Presentation EURETINA 2025. 2. Campochiaro PA, et al. Ophthalmol Retina. 2025;9(2):144-155. 3. Khanani AM, et al. Ophthalmol Retina. 2021;5(8):775–787. 4. Holekamp NM, et al. Ophthalmology. 2022;129(3):295–307. Prior PDS 100 mg/mL (n=59) Prior IVT ranibizumab 0.5 mg (n=41) SUSVIMO delivers vision preservation, but adoption limited by surgical procedure3,4

Page 16

© 2026 4D Molecular Therapeutics. All Rights Reserved. 16 We Believe Continuous Disease Control from 4D-150 Backbone Therapy Can Close the Long-term Vision Outcomes Gap in Wet AMD VISUAL ACUITY TIME 4D-150 Backbone Therapy: continuous anti-VEGF for continuous disease control CONTINUOUS CONTROL GAP Initial response is not the challenge The challenge is not achieving an initial response. The challenge is preserving vision over time.

Page 17

Page 18

© 2026 4D Molecular Therapeutics. All Rights Reserved. 18 4D-150 Has Been Evaluated Across Diverse Wet AMD Populations and Demonstrated Strong Proof-of-Concept 1/2a PRISM Phase 1/2a Severe, Recalcitrant 2b PRISM Phase 2b Broad 2b PRISM Phase 2b Subgroup Recently diagnosed, Phase 3-comparable 3 4FRONT Phase 3 T reatment naïve, recently diagnosed Strong data in diverse populations improved confidence in Phase 3 dose selection and design

Page 19

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 19 PRISM Phase 1/2a Severe, recalcitrant 4D-150 Has Been Evaluated Across Diverse Wet AMD Populations and Demonstrated Strong Proof-of-Concept 3 4FRONT Phase 3 T reatment naïve, recently diagnosed PRISM Phase 2b 2b Broad 2b PRISM Phase 2b Subgroup Recently diagnosed, Phase 3-Comparable 1/2a Strong data in diverse populations improved confidence in Phase 3 dose selection and design

Page 20

© 2026 4D Molecular Therapeutics. All Rights Reserved. 20 Data cutoff of May 18, 2026. SD, standard deviation; BL, baseline; CST, central subfield thickness; BCVA, best corrected visual acuity; ETDRS, early treatment diabetic retinopathy study. *Projection based on last loading dose in Phase 2b and approved dosing schedule for aflibercept in wet AMD. Visual Acuity & Anatomy Stable With Robust Reduction in Treatment Burden 2-Year Results in Broad Population Anatomy & Visual Acuity Post–4D-150 Treatment Burden Reduction Post–4D-150 Central Subfield Thickness Best-Corrected Visual Acuity 2 Years Post–4D-150 2 Years Projected* –78% Aflibercept 4D-150 -150 -100 -50 0 50 100 150 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 Mean ±SD Change from BL in CST (µm) Week 3E10 vg/eye (n=30) -40 -30 -20 -10 0 10 20 30 40 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 Mean ±SD Change from BL in BCVA (ETDRS letters) Week 13% 2 injections 46% Injection free 10% 1 injection 31% >2 injections 12.0 2.7

Page 21

© 2026 4D Molecular Therapeutics. All Rights Reserved. 21 Data cutoff of May 18, 2026. SD, standard deviation; BL, baseline; CST, central subfield thickness; BCVA, best corrected visual acuity; ETDRS, early treatment diabetic retinopathy study. *Projection based on last loading dose in Phase 2b and approved dosing schedule for aflibercept in wet AMD. Visual Acuity & Anatomy Stable With Robust Reduction in Treatment Burden 2-Year Results in Recently Diagnosed Population (Phase 3-Comparable) Anatomy & Visual Acuity Post–4D-150 Treatment Burden Reduction Post–4D-150 Central Subfield Thickness Best-Corrected Visual Acuity 2 Years Post–4D-150 2 Years Projected* –87% -150 -100 -50 0 50 100 150 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 Mean ±SD Change from BL in CST (µm) Week 3E10 vg/eye (n=15) -40 -30 -20 -10 0 10 20 30 40 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 Mean ±SD Change from BL in BCVA (ETDRS letters) Week Aflibercept 4D-150 14% 2 injections 66% Injection free 7% 1 injection 13% >2 injections 12.0 1.6

Page 22

© 2026 4D Molecular Therapeutics. All Rights Reserved. 22 Highest SUN/NEI Score† with 4D-150 3E10 vg/eye (N=71) PRISM Phase 1/2 Follow-up Suggests a Favorable, Predictable Long-term Safety Profile Through 2-4+ Years (N=71 at Phase 3 Dose) Data cutoff of May 18, 2026. NEI, National Eye Institute; SUN, Standardization of Uveitis Nomenclature. †4D-150–related. ‡1+ VC cell in 1 patient at Week 4 & 1 patient Week 28.  No 4D-150–related serious adverse events  No 4D-150–related hypotony, endophthalmitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions None 1+ 3+ 4+ 2+ Through Week 28 After Week 28 to Yea r 1 Y ear 2 to 4+ Prophylactic corticosteroid (~20 weeks) Y ear 1 to 2

Page 23

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 23 4D-150 Demonstrated the Potential to Provide Durable Disease Control With Robust Reduction in Treatment Burden with a Favorable Safety Profile Data cutoff of May 18, 2026. Strong differentiated profile generated in Phase 1/2 for evaluation in Phase 3. ROBUST REDUCTION IN TREATMENT BURDEN AND STRONG INJECTION -FREE RATE ADVANCED TO GLOBAL PIVOTAL PROGRAMS STABLE VISION AND ANATOMY FAVORABLE, PREDICTABLE SAFETY PROFILE

Page 24

Page 25

© 2026 4D Molecular Therapeutics. All Rights Reserved. 25 Global 4FRONT Phase 3 Wet AMD Program Summary *1-4 prior injections, diagnosed within 6 months. BCVA, Best Corrected Visual Acuity; RMAT, Regenerative Medicine Advanced Therapy; PRIME, Priority Medicines; PMDA, Pharmaceuticals and Medical Devices Agency. North America 100% Treatment naïve Global ≥60% Treatment naïve Up to 40% Previously treated*  Regulatory alignment: • FDA RMAT designation • EMA PRIME designation • Japan PMDA interactions  Robustly powered for global approval standards (~4 letter noninferiority margin) Primary Objective Noninferiority in mean change in BCVA from baseline to Week 52 for a single injection of 4D-150 vs. aflibercept 2mg (Q8W) after 3 loading doses  N=523 randomized (exceeded N=480 target)  N=531 randomized (exceeded N=480 target)

Page 26

© 2026 4D Molecular Therapeutics. All Rights Reserved. 2626 Arshad Khanani MD, MA, FASRS Chair Carl Awh MD, FASRS David Boyer MD Frank Holz MD, FEBO, FARVO Anat Loewenstein MD, MHA Phase 3 Development Strategy Guided by Global Retina Advisory Board Gemmy Cheung MBBS, FRCOphth, FAMS, MCI Yuichiro Ogura MD, PhD Dante Pieramici MD Patricio Schlottmann MD Sobha Sivaprasad DM, FRCS, FRCOphth

Page 27

© 2026 4D Molecular Therapeutics. All Rights Reserved. 27 Global 4FRONT Phase 3 Trial Design: Patient Population Optimized Primary endpoint Durezol® taper (both arms) starting Day -3 Screening Response Week -5 -1 D1 4 8 12 16 20 24 28 32 36 40 44 48 52 104 4D-150 3E10 vg/eye                 Aflibercept 2 mg                   4D-150  Aflibercept Sham injection Randomize (Baseline) Global, Multicenter, Randomized, Double Masked, Aflibercept Q8W Comparator Controlled Studies ≥15% reduction in CST or complete resolution of intraretinal and/or subretinal fluid* Enrolling selected population to reduce variability:  Excluded outlier baseline anatomy (high CST) that drives variability  Randomizing strong aflibercept responders only *Determined by SD-OCT and confirmed by an independent Reading Center. BCVA: 25-78 letters CST: ≤500 µm Active disease

Page 28

© 2026 4D Molecular Therapeutics. All Rights Reserved. 28 Global 4FRONT Phase 3 Trial Design: Supplemental Injection Criteria Optimized *Determined by SD-OCT and confirmed by an independent Reading Center. †PI discretion not allowed. Primary endpoint Durezol® taper (both arms) starting Day -3 Week -5 -1 D1 4 8 12 16 20 24 28 32 36 40 44 48 52 104 4D-150 3E10 vg/eye                 Aflibercept 2 mg                   4D-150  Aflibercept Sham injection Global, Multicenter, Randomized, Double Masked, Aflibercept Q8W Comparator Controlled Studies Reference Values: BCVA: Average of Week 4 & 8 CST: Week 8 Disease Activity (if any criteria are met)†: Vision & Anatomy: ≥5 letter loss in BCVA AND ≥50 µm increase in CST Vision : ≥10 letter loss in BCVA Anatomy: ≥100 µm increase in CST New vision-threatening hemorrhage Optimized Supplemental Criteria  Protects BCVA  Clinically relevant treatment burden reduction result Supplemental Aflibercept Criteria (Both arms)

Page 29

© 2026 4D Molecular Therapeutics. All Rights Reserved. 29 Injection Burden in Perspective (Bolus IVT Therapies): Annualized Injections1 Post-Loading in Year 1 of Phase 3 Trials Annualized injection comparisons across studies should be interpreted with caution due to differences in study design, dosing regimens, treatment protocols, patient populations, and follow-up duration. Dosing intervals are as described in each individual study and may not be directly comparable. 1. Lucentis, Eylea, Vabysmo, Eylea HD, Zenkuda annualized injections post-loading implied with weighted average of % of patients assigned to dosing interval at Phase 3 primary endpoint applied to annualized injections implied by interval (i.e., 52 weeks ÷ Q12 week = 4.3 annualized injections). Sources: Lucentis package insert; Eylea 2mg package insert; Heier JS, et al. Lancet. 2022;399:729–740 (TENAYA/LUCERNE); Lanzetta P, et al. Lancet. 2024;403:1141–1152 (PULSAR); Kodiak Daybreak Webcast, September 28, 2026. 13.0 6.5 4.3 4.3 3.6 1.0 0.3 (Q4W) (Q8W) (Q8-16W) (Q8-16W) Zenkuda (Q4-24W) 4D-150 Ph2b 4D-150 Ph2b Annualized Injections Post-Loading 0% 0% 0% 0% 0% 57% 80%Injection-free Phase 2b

Page 30

© 2026 4D Molecular Therapeutics. All Rights Reserved. 30 0% 0% 0% 0% 0% 57% 80% 4D-150 Annualized Mean Injections and Injection-free % Could Represent a Best-in-Disease Profile Annualized injection comparisons across studies should be interpreted with caution due to differences in study design, dosing regimens, treatment protocols, patient populations, and follow-up duration. Dosing intervals are as described in each individual study and may not be directly comparable. Lucentis, Eylea, Vabysmo, Eylea HD, Zenkuda annualized injections post-loading implied with weighted average of % of patients assigned to dosing interval at Phase 3 primary endpoint applied to annualized injections implied by interval (i.e., 52 weeks ÷ Q12 week = 4.3 annualized injections). Sources: Lucentis package insert; Eylea 2mg package insert; Heier JS, et al. Lancet. 2022;399:729–740 (TENAYA/LUCERNE); Lanzetta P, et al. Lancet. 2024;403:1141–1152 (PULSAR); Kodiak Daybreak Webcast, September 28, 2026. 1. Data cutoff of May 18, 2026. Annualized supplemental injections post-loading in Year 1. 13.0 6.5 4.3 4.3 3.6 1.0 0.3 (Q4W) (Q8W) (Q8-16W) (Q8-16W) Zenkuda (Q4-24W) 4D-150 Broad Population 4D-150 Recently Diagnosed Pop. Annualized injections Post-Loading Phase 2b 4D-150 Broad 4D-150 Phase 3-Comparable Injection-free

Page 31

© 2026 4D Molecular Therapeutics. All Rights Reserved. 3131 4D-150 Designed to Achieve the Ideal Product Profile For Wet AMD that Closes the Continuous Control Gap IVT = Intravitreal. A POTENTIAL BACKBONE THERAPY FOR CONTINUOUS DISEASE CONTROL Lifelong, continuous anti-VEGF with adherence by design Long-term vision preservation Robust treatment burden reduction and injection-free rate Favorable, predictable safety profile Single, in-office IVT injection

Page 32

© 2026 4D Molecular Therapeutics. All Rights Reserved. 32 Carl Awh MD, FASRS T ennessee Retina Dhaval Desai, PharmD Chief Development Officer Arshad Khanani MD, MA, FASRS Sierra Eye Associates KOL PANEL DISCUSSION Promise of 4D-150 in Wet AMD MODERATOR PANELISTS

Page 33

Page 34

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 3434 Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, regulatory interactions, timing, strategy, future operations, future financial position, prospects, plans, objectives of management, and implied and express statements regarding the therapeutic potential, treatment burden reduction, durability and clinical benefits of and market potential of our product candidates are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation. This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied. Our discussion of the potential commercial opportunity reflects our current expectations and estimates, and is subject to significant uncertainties. There can be no assurance that clinical development will be successful, that regulatory approval will be obtained, or that it will be commercialized. Any estimates of market opportunity or future commercial potential are preliminary and subject to change. This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

Page 35

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 35 Commercial Success Starts with Meeting Stakeholder Needs 1. Primary quantitative research with retina specialists (n=75), Apr 2026; From Episodic Disease Control Toward Continuous Disease Control of Retina Specialists agree a Backbone Therapy approach would shift the treatment paradigm to enable long-term disease control1 85% Retina Specialists need more than incremental durability gains and a better way to preserve their patients’ vision Payers need a treatment that keeps patients on therapy, preserves their vision over time and delivers lasting value Patients need confidence in lasting vision protection and relief from the high burden of bolus injections Retina Practices need less administrative work, more clinic capacity and confidence in reimbursement

Page 36

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 36 4D-150 Designed to Achieve the Ideal Product Profile For Wet AMD that Closes the Continuous Control Gap A POTENTIAL BACKBONE THERAPY FOR CONTINUOUS DISEASE CONTROL Lifelong, continuous anti-VEGF with adherence by design Long-term vision preservation Robust treatment burden reduction and injection-free rate Favorable, predictable safety profile Single, in-office IVT injection IVT = Intravitreal.

Page 37

© 2026 4D Molecular Therapeutics. All Rights Reserved. 37 As a Backbone Therapy, 4D-150 is Uniquely Positioned to Address the Greatest Unmet Needs: Continuous Disease Control and Vision Preservation Colored logos denote select commercially available wet AMD products in the United States; *gray logos denote companies that do not currently market a wet AMD product in the United States (as of October 21, 2026). Supplemental bolus treatment options available if needed 4D-150 Backbone Therapy for Continuous Disease Control AVAILABLE TODAY IN DEVELOPMENT*

Page 38

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 38 T oday’s Agenda: The Commercial Opportunity 1 The Market 2 The Patient Perspective KOL PERSPECTIVE Patient Burden, Unmet Need & The Future Patient Experience 3 Retina Specialists’ Perspective 4 Clinic Economics & Operations 5 Payers & Reimbursement KOL PERSPECTIVE From Clinical Value to Real-World Adoption

Page 39

© 2026 4D Molecular Therapeutics. All Rights Reserved. 39 A Growing Retina Branded Anti-VEGF Market that is Approaching $16B Globally, of which ~60% is US WET AMD ~$9.5B The anchor indication for anti-VEGF therapy DME ~$5B Growing alongside diabetes prevalence Average Annual Growth Rate of 5% over the last 10 years 2026E global branded retinal vascular disease anti-VEGF market estimated using GlobalData market forecasts, public company disclosures, and company analysis. Other retinal indications (RVO etc.) contribute to remainder of estimated market size. Estimates are subject to underlying source assumptions and methodology. DME = Diabetic Macular Edema.

Page 40

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 40 Modest Durability Gains Have Driven Commercial Success 1. Lucentis package insert. 2. TRUCKEE Study. Injection burden reduction vs. prior therapy implied based on difference in calculated annual injections based on TRUCKEE durability. 3. Vestrum Health Custom Analysis of PPD Real-World Data. 0% of patients have injection-free potential Across all bolus therapies: of patients have multi-year, continuous disease control AND ~30 days $1.8B ~44 days ~30% $3.3B ~57 days ~25% $4.4B — THERAPY AVERAGE INTERVAL1,2 VS. PRIOR NET SALES, YR 3 In real-world practice, the durability interval has only increased by +12 days or <1 fewer injection per year3 0%

Page 41

© 2026 4D Molecular Therapeutics. All Rights Reserved. 41 Growing Patient Populations & High Bilateral Rate of Disease Further Expands the US Opportunity 1. IQVIA Custom Market Mapping Study (Jan 2024) with forward growth projections based on US Census and 4DMT internal estimates. 2. Fasler K, Fu DJ, Moraes G, et al. The Moorfields AMD Database Report 2: Fellow Eye Involvement with Neovascular Age-Related Macular Degeneration. Br J Ophthalmol. 2020;104(5):684-690. 3. Kulkarni P, Chang SC, Chuo CY, et al. Bilateral macular edema at baseline and 1 year due to diabetic retinopathy, neovascular age-related macular degeneration, and retinal vein occlusion. IOVS. 2021;62(8). 600,000 (~160,000 newly treated) 700,000 (~190,000 newly treated) 900,000 (~250,000 newly treated) Wet AMD (~ 30 to 40% bilateral disease3) 1,700,000 eyes are estimated to be treated in the US alone by 2030 800,000 (~210,000 newly treated) To d ay By 2030 DME (~50% bilateral disease3) To d ay By 2030 400,000 (~170,000 newly treated) 600,000 (~250,000 newly treated) 500,000 (~200,000 newly treated) 800,000 (~300,000 newly treated) Treated Patients1 Treated Eyes2 Treated Patients1 Treated Eyes2

Page 42

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 42 T oday’s Agenda: The Commercial Opportunity 1 The Market 2 The Patient Perspective KOL PERSPECTIVE Patient Burden, Unmet Need & The Future Patient Experience 3 Retina Specialists’ Perspective 4 Clinic Economics & Operations 5 Payers & Reimbursement KOL PERSPECTIVE From Clinical Value to Real-World Adoption

Page 43

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 43 Arduous & Emotional Patient Journey: Burden Accumulates Before, During and After Every Injection Primary wet AMD patient research (n=40; mixed methods), Oct 2025. Weeks to months before: Anticipation Patients organize their life around the appointment, often worrying about vision results, bad news and the injection itself Several hours: Dependence Many patients must rely on family members, friends or caregivers for transportation and support Hours: Apprehension Exams, dilation, imaging and waiting can stretch the visit for hours while anxiety builds 5–10 min injection: Distress The procedure is brief, but the anticipation of a needle in the eye is one of the most emotionally difficult parts of treatment Hours to days: Recovery Patients may experience soreness, light sensitivity, visual disruption for hours or days THE BURDEN REPEATS WITH EVERY INJECTION DREAD GUILT ANXIETYFEAR EXHAUSTION

Page 44

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 44 Fear of Vision Loss Persists Despite Ongoing Treatment Primary Wet AMD patient research (n=40, mixed-methods), Oct 2025. THE FEAR OF VISION LOSS “I don’t want to go blind” “I’m kind of depressed that I’m going blind” — Wet AMD patients “My biggest fear is losing my vision” “You lose the ability to see faces…and suddenly you’re on the outside”

Page 45

Page 46

© 2026 4D Molecular Therapeutics. All Rights Reserved. 46 Despite Commitment to Preserving Vision, Many Patients Struggle to Sustain the Treatment Burden 1. Moshfeghi DM, et al. Invest Ophthalmol Vis Sci. 2026;67:5268. ARVO 2026.; 2. Vakharia PS, et al. Invest Ophthalmol Vis Sci. 2026;67:5267. ARVO 2026. 3. Primary Wet AMD patient research (n=40; mixed methods), Oct 2025 Competing comorbidities Caregiver burden, travel, logistics Increased stress, anxiety and depression T reatment fatigue UP TO 40% of patients stop treatment by 12 months 1,2 WHY THEY STOP 3 Over time, treatment burden contributes to gaps in care, discontinuation and ultimately poorer visual outcomes

Page 47

© 2026 4D Molecular Therapeutics. All Rights Reserved. 47 Strong Patient Demand Could Accelerate Adoption of 4D-150 Primary Wet AMD patient research (n=40; mixed-methods), Oct 2025. PATIENTS ARE HIGHLY RECEPTIVE TO 4D -150 AND THEY ARE MOTIVATED TO ACT “This would take a lot of the anxiety away” “Wow… my husband wouldn’t have to drive me every four weeks” “It sounds amazing… it’s a game-changer” ~90% of patients would talk to their doctor about 4D-150

Page 48

© 2026 4D Molecular Therapeutics. All Rights Reserved. 48 Sara Haug MD, PhD Southwest Retina Consultants Catherine Pajak Vice President, Commercial KOL DISCUSSION Patient Burden, Unmet Need & The Future Patient Experience MODERATOR PANELIST

Page 49

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 49 T oday’s Agenda: The Commercial Opportunity 1 The Market 2 The Patient Perspective KOL PERSPECTIVE Patient Burden, Unmet Need & The Future Patient Experience 3 Retina Specialists’ Perspective 4 Clinic Economics & Operations 5 Payers & Reimbursement KOL PERSPECTIVE From Clinical Value to Real-World Adoption

Page 50

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 50 Large Market Opportunity with Specialty Physician Community 1. IQVIA Health Care Professional concentration analysis, Jul 2026. 2. Primary quantitative research with retina specialists (n=75), Apr 2026; wAMD = Wet AMD. Just 10 organizations represent >25% of all patient volume 40% Retina Specialists report minimal capacity to treat additional patients2 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 500 1,000 1,500 2,000 2,500 3,000 Cumulative % wAMD Patients Cumulative # of Retina Specialists US Retina Specialists Concentration Curve1 1,250 Retina Specialists represent 90% of patient volume

Page 51

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 51 Retina Specialists Are Eager to Utilize 4D-150 Backbone Therapy CST, central subfield thickness. 1. Primary quantitative research with retina specialists (n=75), Apr 2026. patients with significant healthcare burden 92% patients who fear injections 90% patients who miss appointments 89% patients with CST fluctuations 92% patients losing visual acuity 77% Retina Specialists are open to prescribing to different patient types 1 newly diagnosed patients 50% of Retina Specialists intend to prescribe to 75% of Retina Specialists would prescribe within 1 year of approval1

Page 52

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 52 Initial Adoption Driven by High Need Patients, and Expanding to Broad Population Over Time 1. Vestrum Health Custom Analysis of PPD Real-World Data . Based on the ~900K projected treated wAMD patients in 2030, segment sizes would equate to approximately 200K high-burden, 400K moderate-burden, and 300K low-burden eyes. 2. Primary quantitative research with retina specialists (n=75), Apr 2026. Intent to prescribe is based on clinical criteria only. INITIAL ADOPTION 1 High burden 25% of eyes with 8 or more injections per year1 EXPANDING USE 2 Moderate burden 45% of eyes with 5 to 7 injections per year 1 BROADER POPULATION 3 Low burden 30% of eyes with 4 or fewer injections per year 1 Adoption Expands with Reimbursement Confidence Real-World Safety Patient Demand Retina Specialists’ Intent to Prescribe 4D-150 Across Patient Segments2 ~40% of patients who receive more than 6 annual injections ~30% of patients who receive 6 or fewer annual injections of newly diagnosed patients~20%

Page 53

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 53 The Combination of Patient and Retina Specialist Enthusiasm Can Drive Adoption for 4D-150 1. Primary Wet AMD patient research (n=40; mixed-methods), Oct 2025. 2. Primary quantitative research with retina specialists (n=75), Apr 2026. 3. 4DMT Retina Specialist Advisory Board, Q1 2026. PATIENT MOTIVATION ~90% of wet AMD patients say would talk to their doctor about 4D-1501 RETINA SPECIALIST INTENT 90% of Retina Specialists are likely to prescribe 4D-150 if a patient asks2 “Patients love gene therapy - they always ask about it” — Retina Specialist 3

Page 54

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 54 T oday’s Agenda: The Commercial Opportunity 1 The Market 2 The Patient Perspective KOL PERSPECTIVE Patient Burden, Unmet Need & The Future Patient Experience 3 Retina Specialists’ Perspective 4 Clinic Economics & Operations 5 Payers & Reimbursement KOL PERSPECTIVE From Clinical Value to Real-World Adoption

Page 55

© 2026 4D Molecular Therapeutics. All Rights Reserved. 55 4D-150 Would Integrate Seamlessly with the Current Buy-and-Bill Reimbursement Model ASP = Average Selling Price. Buy-and- Bill Flow Practice Purchases Product Practice Receives Reimbursement (ASP + % margin) Practice Administers Product in Office Practice Bills Payer

Page 56

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 56 4D-150 has the Potential to Capture Lost Value TODAY’S PRACTICE ECONOMICS Injection frequency TOMORROW’S OPPORTUNITY WITH 4D -150 Multi-year reimbursement Value created through Value eroded by Value amplified by No injection → no reimbursement One treatment → upfront value capture Patient drops off → reimbursement stops No patient drops off → limits financial risk Capacity constraints → limited reimbursable events Capacity freed up → additional revenue opportunity from other/new patients

Page 57

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 57 T oday’s Reality: High Clinic Workload and Partial Value Capture 1 Assumes 6 injections per year per patient. 2. Calculation based on real world injection frequency (Wykoff et al., 2023) plus discontinuation rate assumptions Bolus anti-VEGF patient Discontinued patient How much value can be captured from 10 patients over 5 years? Potential Anti-VEGF Treatment1 300 T otal Injections Over 5 Years Average 30 injections per patient1 Actual Real-World Anti-VEGF Treatment2 160 T otal Injections Over 5 Years Average 16 injections per patient2 Capturing Full Five-Year Potential Value Requires 100% of patients stay on treatment for 5 years 300 visits 300 injections 300 benefits investigations & other back-office work 300 incidents of full reimbursement Yr 2 Yr 1 Yr 3 Yr 4 Yr 5 Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Illustrative Drug Reimbursement Potential 100% Actual Real-World 53%

Page 58

© 2026 4D Molecular Therapeutics. All Rights Reserved. 58 4D-150 patient T omorrow’s Potential: Significantly Lower Clinic Workload and Full Value Capture *Illustrative and not intended to be indicative of product pricing; final value will depend on post-approval list-price. 100% of Potential as defined by the final pricing of 4D-150. How do you get there over 5 years with 10 patients… Potential Future With 4D-150 10 T otal Injections 1 injection per patient Capturing Full Illustrative Value Across 10 Patients Requires 10 visits 10 injections 10 benefits investigations & other back-office work 10 incidents of full reimbursement Illustrative Drug Reimbursement* 100% How much value can be captured from 10 patients with 4D-150? Yr 1 Yr 2 Yr 3 Yr 4 Yr 5

Page 59

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 59 4D-150 Has the Potential to Reduce Injection Workload While Preserving Practice Economics *Illustrative and not intended to be indicative of product pricing; final value will depend on post-approval list-price. 100% of Potential as defined by the final pricing of 4D-150. Illustrative Five-Year Impact Across 10 Patients Potential Anti-VEGF Treatment300 Actual Real-World Anti-VEGF Treatment160 Potential Future with 4D-15010 Illustrative Drug Reimbursement 100% 53% 100%*

Page 60

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 6060 T oday’s Agenda: The Commercial Opportunity 1 The Market 2 The Patient Perspective KOL PERSPECTIVE Patient Burden, Unmet Need & The Future Patient Experience 3 Retina Specialists’ Perspective 4 Clinic Economics & Operations 5 Payers & Reimbursement KOL PERSPECTIVE From Clinical Value to Real-World Adoption

Page 61

© 2026 4D Molecular Therapeutics. All Rights Reserved. 61 Medicare Part B is the Primary Payer for Wet AMD Patients, Covering ~90% of Patients 1. Trinity analysis of Komodo Healthcare Map® claims data (Jan 2025-May 2026; U.S. Wet AMD patients). 2. Modeled estimate based on Komodo claims data, published cost-sharing benchmarks, patient OOP maximums, and estimated commercial copay assistance. 88% Medicare Medicare AdvantageMedicare Fee-for-Service 51%37% Commercial 10%Medicaid 2% US WET AMD PAYER MIX¹ ~70% of wet AMD patients currently have $0 incremental out-of-pocket exposure2 Implications of Medicare Part B Reimbursement: Positions 4D-150 for broad patient access Fits within the buy-and-bill reimbursement framework that retina practices navigate everyday

Page 62

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 62 Current Bolus Anti-VEGF Treatment Generate Substantial Cumulative Costs while Patients Experience Vision Decline 1. Wykoff et al.: Ophthalmol Sci. 2023 Oct 31;4(2):100421.; n=135,384 at Yr 1; 6,878 at Yr 6. 2. Singer MA, et al. Ophthalmology. 2012;119(6):1175–83. 3. Silva R, et al. Ophthalmology. 2012;120:130–39. 4. Maguire MG, et al. Ophthalmology. 2016;123:1751–61. 5. Khanani A, et al. Ophthalmology. 2019;4(2):122–33. 6. Ciulla T, et al. Ophthalmology. 2019;4(1):19–30. 7. Arpa C, et al. Br J Ophthalmol. 2021;105(12):1688–95. 2. *Illustrative cumulative drug cost based on bolus anti-VEGF treatment, using 6.0-6.5 injections / year and 3Q2026 Annual Selling Price per-injection cost. Drug acquisition cost only; excludes administration and other medical costs. Cumulative Cost to Payer Real-World Outcomes1-7 Up to $73K Cumulative anti-VEGF treatment bolus treatment cost Illustrative drug costs over 5 years* Treatment burden remains ongoing Patients lose vision

Page 63

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 63 Payers Agree: Vision Preservation is the Goal and Current Treatment Falls Short Primary Payer Research July 2026 (n=15, ~134M covered lives). Long-term Vision Preservation of payers agree that the goal of long-term treatment in wet AMD is ongoing protection against vision loss 73% of payers agree achieving long-term real-world vision preservation is a limitation with existing bolus therapies “The expectation is that these patients [on bolus therapy] are going to progress” 100% 87% of payers acknowledge the need for an improved therapy in wet AMD Ongoing protection against vision loss is the unifying goal of treatment — Director, National Managed Care Organization

Page 64

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 64 And Payers Recognize the Potential and the Promise Primary Payer Research: Qualitative (n=6) and Quantitative, (n=15), July 2026; Gene Therapy is Promising of payers view gene therapy as the most promising mechanism to address unmet needs in wet AMD71% 80% View “backbone treatment” potential as impactful in coverage decisions 93% Agree that new treatments should focus on maintaining continuous disease control Early research suggests Payers support coverage of 4D-150 across a broad price range

Page 65

© 2025 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. 65 4D-150 is a Backbone Therapy That Has the Potential to Meet the Needs of Key Stakeholders With 4D-150, there is the potential to move from variability and uncertainty toward continuous disease control Retina Specialists see a clear clinical role and adoption path, driven by the possibility of continuous disease control and a better way to preserve their patients’ vision Payers value the potential of lifelong adherence, significant reduction in bolus treatment and the preservation of vision Patients are motivated to act, driven by the potential for lasting vision protection and treatment burden relief Retina Practices could seamlessly integrate 4D-150 into existing workflows with the potential to reduce administrative work, create capacity and improve clinic economics

Page 66

© 2026 4D Molecular Therapeutics. All Rights Reserved. 66 David Eichenbaum MD, FASRS Retina Vitreous Associates of Florida Chris Simms Chief Commercial & Business Officer KOL DISCUSSION From Clinical Value to Real-World Adoption MODERATOR PANELIST

Page 67

Page 68

© 2026 4D Molecular Therapeutics. All Rights Reserved. 68 An Experienced Leadership T eam Positioned to Deliver 4D-150 to Patients David Kirn, MD Co-Founder, President & CEO Julie Clark, MD Chief Medical Officer Dhaval Desai, PharmD Chief Development Officer Kim Maplestone Chief Clinical Operations Officer Scott Bizily, JD, PhD Chief Legal Officer Chris Simms Chief Commercial & Business Officer Kristian Humer Chief Financial Officer Theresa Janke Chief of Staff, Co-Founder Katy Barglow, PhD Chief T echnical Officer

Page 69

© 2026 4D Molecular Therapeutics. All Rights Reserved. 69 Proven Board of Directors to Guide Path to Commercialization John F. Milligan, PhD Executive Chairman Jacob Chacko, MD, MBA Susannah Gray, MBA Nancy Miller-Rich Glenn P . Sblendorio Charles Theuer, MD, PhD Shawn T omasello, MBA

Page 70

© 2026 4D Molecular Therapeutics. All Rights Reserved. 70 Key Catalysts: Poised for Strong Clinical Data & Phase 3 Execution Milestones followed by T opline Phase 3 Data *Cash, cash equivalents and marketable securities as of June 30, 2026.  Feb 2026: 4FRONT-1 Phase 3 enrollment complete  Jun 2026: 4FRONT-2 Phase 3 enrollment complete  Jul 2026: PRISM Phase 2b 2-year data  Q2 2027: 4FRONT-1 Phase 3 topline data  H2 2027: 4FRONT-2 Phase 3 topline data  Sep 2026: Announced 4SIGHT Global Phase 3 design & trial initiation  Sep 2026: SPECTRA Trial Part 1 2-year data $431M Cash*, Runway Expected into H2 2028 Wet AMD Diabetic Macular Edema  October 21, 2026: Investor Day in New Y ork City highlighting the commercial potential of 4D-150 Corporate

Page 71

© 2026 4D Molecular Therapeutics. All Rights Reserved. 71 Key Takeaways For T oday Backbone therapy with the potential for lifelong, continuous disease control from a single dose1 Clinical trial data, Phase 3 design and strong execution positions us for success3 Target product profile that addresses the key unmet needs of patients : preserving vision while reducing treatment burden , with an opportunity for injection - freedom 2 Patients, physicians and payers together are expected to drive robust and broad commercial adoption 4 4D-150 Has the Potential to Establish A NEW TREATMENT PARADIGM IN WET AMD

Page 72

© 2026 4D Molecular Therapeutics. All Rights Reserved. © 2026 4D Molecular Therapeutics. All Rights Reserved. THANK YOU 5858 Horton Street, Suite 455 | Emeryville, California 94608 (510) 505-2680 | Investor.Relations@4DMT.com IR.4DMT.com | LinkedIn

Slides

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6

Page 7

Page 8

Page 9

Page 10

Page 11

Page 12

Page 13

Page 14

Page 15

Page 16

Page 17

Page 18

Page 19

Page 20

Page 21

Page 22

Page 23

Page 24

Page 25

Page 26

Page 27

Page 28

Page 29

Page 30

Page 31

Page 32

Page 33

Page 34

Page 35

Page 36

Page 37

Page 38

Page 39

Page 40

Page 41

Page 42

Page 43

Page 44

Page 45

Page 46

Page 47

Page 48

Page 49

Page 50

Page 51

Page 52

Page 53

Page 54

Page 55

Page 56

Page 57

Page 58

Page 59

Page 60

Page 61

Page 62

Page 63

Page 64

Page 65

Page 66

Page 67

Page 68

Page 69

Page 70

Page 71

Page 72

Sign in to continue

Slides

Page 1

Page 2

Page 3

Page 4

Page 5